CA3219858A1 - Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines - Google Patents
Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines Download PDFInfo
- Publication number
- CA3219858A1 CA3219858A1 CA3219858A CA3219858A CA3219858A1 CA 3219858 A1 CA3219858 A1 CA 3219858A1 CA 3219858 A CA3219858 A CA 3219858A CA 3219858 A CA3219858 A CA 3219858A CA 3219858 A1 CA3219858 A1 CA 3219858A1
- Authority
- CA
- Canada
- Prior art keywords
- general formula
- compound
- cancer
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110565410.0 | 2021-05-24 | ||
| CN202110565410 | 2021-05-24 | ||
| CN202110694022.2 | 2021-06-22 | ||
| CN202110694022 | 2021-06-22 | ||
| CN202110856289 | 2021-07-28 | ||
| CN202110856289.7 | 2021-07-28 | ||
| CN202210198679.4 | 2022-03-02 | ||
| CN202210198679 | 2022-03-02 | ||
| PCT/CN2022/094612 WO2022247816A1 (zh) | 2021-05-24 | 2022-05-24 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219858A1 true CA3219858A1 (en) | 2022-12-01 |
Family
ID=84229501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219858A Pending CA3219858A1 (en) | 2021-05-24 | 2022-05-24 | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240287094A1 (https=) |
| EP (1) | EP4349836A4 (https=) |
| JP (1) | JP2024519188A (https=) |
| KR (1) | KR20240012437A (https=) |
| CN (1) | CN117177971A (https=) |
| AU (1) | AU2022280845A1 (https=) |
| BR (1) | BR112023022496A2 (https=) |
| CA (1) | CA3219858A1 (https=) |
| MX (1) | MX2023013890A (https=) |
| TW (1) | TW202313630A (https=) |
| WO (1) | WO2022247816A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| WO2024041643A1 (zh) * | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| CN120035596A (zh) * | 2022-11-23 | 2025-05-23 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| KR20260021657A (ko) | 2023-06-08 | 2026-02-13 | 상하이 센후이 메디슨 컴퍼니 리미티드 | 포름아미드계 화합물의 제조 방법 |
| WO2024255697A1 (zh) * | 2023-06-13 | 2024-12-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) * | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| TWI693218B (zh) | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| TWI715291B (zh) * | 2018-11-16 | 2021-01-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 包含parp抑制劑的藥物組合物 |
| SI3999506T1 (sl) * | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| AU2021298145A1 (en) | 2020-06-24 | 2023-02-09 | Itf Research Pharma, S.L.U | Soft gelatin capsules |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| US11591331B2 (en) * | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| JP7835895B2 (ja) * | 2022-05-07 | 2026-03-25 | サイブランチ セラピューティクス カンパニー リミテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
-
2022
- 2022-05-24 BR BR112023022496A patent/BR112023022496A2/pt unknown
- 2022-05-24 JP JP2024515728A patent/JP2024519188A/ja active Pending
- 2022-05-24 CA CA3219858A patent/CA3219858A1/en active Pending
- 2022-05-24 MX MX2023013890A patent/MX2023013890A/es unknown
- 2022-05-24 EP EP22810541.7A patent/EP4349836A4/en active Pending
- 2022-05-24 WO PCT/CN2022/094612 patent/WO2022247816A1/zh not_active Ceased
- 2022-05-24 TW TW111119308A patent/TW202313630A/zh unknown
- 2022-05-24 US US18/562,127 patent/US20240287094A1/en active Pending
- 2022-05-24 CN CN202280027629.8A patent/CN117177971A/zh active Pending
- 2022-05-24 KR KR1020237042926A patent/KR20240012437A/ko active Pending
- 2022-05-24 AU AU2022280845A patent/AU2022280845A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117177971A (zh) | 2023-12-05 |
| EP4349836A1 (en) | 2024-04-10 |
| TW202313630A (zh) | 2023-04-01 |
| KR20240012437A (ko) | 2024-01-29 |
| WO2022247816A1 (zh) | 2022-12-01 |
| JP2024519188A (ja) | 2024-05-08 |
| AU2022280845A1 (en) | 2023-12-14 |
| BR112023022496A2 (pt) | 2024-01-16 |
| US20240287094A1 (en) | 2024-08-29 |
| EP4349836A4 (en) | 2024-10-30 |
| MX2023013890A (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3219858A1 (en) | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines | |
| EP4361157A1 (en) | Fused tetracyclic compound, preparation method therefor and application thereof in medicine | |
| EP4563580A1 (en) | Fused ring compound, preparation method therefor and medicinal application thereof | |
| CN113801136B (zh) | 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| CN117203207A (zh) | 桥环类化合物、其制备方法及其在医药上的应用 | |
| EP4421076A1 (en) | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof | |
| CN115385937A (zh) | 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用 | |
| CN115368383A (zh) | 稠合含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| CN115385938A (zh) | 苯并嘧啶类化合物、其制备方法及其在医药上的应用 | |
| EP4166555A1 (en) | Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof | |
| CN113845531B (zh) | 吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途 | |
| CN114907349A (zh) | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 | |
| EP4253387A1 (en) | Fused tricyclic compound, preparation method therefor and application thereof in medicine | |
| CN119365468A (zh) | 稠合二环类化合物、其制备方法及其在医药上的应用 | |
| EP4122922A1 (en) | Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof | |
| AU2020407600A1 (en) | Compounds and probes for imaging huntingtin protein | |
| CN113912608A (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 | |
| EP4190789A1 (en) | Oxa-azaspiro derivative, and preparation method therefor and pharmaceutical use thereof | |
| EA051431B1 (ru) | Азотсодержащее гетероциклическое соединение, способ его получения и его применение в качестве ингибитора parp1 | |
| CN113135942B (zh) | 稠合嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| EP4495119A1 (en) | Fused heterocyclic compound, and preparation method therefor and medical use thereof | |
| WO2021143821A1 (zh) | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241017 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250505 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250505 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260421 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260421 |